Effects of cyclosporin A administration on gene expression in rat brain

Brain Injury

Volumn 25, Issue 6, 2011, Pages 614-623

  Kawakami, Minoru ^a   Yoshimoto, Tetsuyuki ^b   Nakagata, Naomi ^a   Yamamura, Ken Ichi ^a   Siesjo, Bo K ^c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kashiwaba Neurosurgical Hospital   (Japan)

^c QUEEN S MEDICAL CENTER   (United States)

Author keywords

brain ischemia; cDNA subtraction; Cyclosporin A; gene expression; neuroprotectant

Indexed keywords

COMPLEMENTARY DNA; CYCLOSPORIN A; ELONGATION FACTOR 1; ELONGATION FACTOR 1 GAMMA; MESSENGER RNA; SYNDECAN 3; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; DRUG EFFECT; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; HUMAN; NEUROPROTECTION;

EID: 79955606253     PISSN: 02699052     EISSN: 1362301X     Source Type: Journal    
DOI: 10.3109/02699052.2011.571229     Document Type: Article

References (102)

1. Shiga Y, Onodera H, Matsuo Y, Kogure K. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Research 1992;595:145-148.
2. Uchino H, Elmer E, Uchino K, Lindvall O, Siesjo BK. Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiologic Scandinavica 1995;155:469-471. (Pubitemid 26017516)
3. Kuroda S, Nakagawa N, Tokunaga C, Tatematsu K, Tanizawa K. Mammalian homologue of the Caenorhabditis elegans UNC-76 protein involved in axonal outgrowth is a protein kinase C zeta-interacting protein. Journal of Cell Biology 1999;144:403-411. (Pubitemid 29234521)
4. Kirino T, Tamura A, Sano K. Delayed neuronal death in the rat hippocampus following transient forebrain ischemia. Acta Neuropathologica 1984;64:139-147. (Pubitemid 14096059)
5. Yamashima T, Tonchev AB, Borlongan CV. Differential response to ischemia in adjacent hippocampalsectors: Neuronal death in CA1 versus neurogenesis in dentate gyrus. Journal of Biotechnology 2007;2:596-607. (Pubitemid 46840048)
6. Uchino H, Elmer E, Uchino K, Li PA, He QP, Smith ML, Siesjo BK. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Research 1998;812:216-226. (Pubitemid 29005351)
7. Wu HY, Tomizawa K, Oda Y, Wei FY, Lu YF, Matsushita M, Li ST, Moriwaki A, Matsui H. Critical role of calpainmediated cleavage of calcineurin in excitotoxic neurodegeneration. Journal of Biological Chemistry 2004;279:4929-4940. (Pubitemid 38199089)
8. 2+induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999;284:339-343.
9. MacKintosh C, MacKintosh RW. Inhibitors of protein kinases and phosphatases. Trends in Biochemical Sciences 1994;19:444-448. (Pubitemid 24342754)
10. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 1994;371:336-339. (Pubitemid 24300615)
11. Butcher SP, Henshall DC, Teramura Y, Iwasaki K, Sharkey J. Neuroprotective actions of FK506 in experimental stroke: In vivo evidence against an antiexcitotoxic mechanism. Journal of Neuroscience 1997;17:6939-6946. (Pubitemid 27427872)
12. Yoshimoto T, Siesjo BK. Posttreatment with the immunosuppressant cyclosporin A in transient focal ischemia. Brain Research 1999;839:283-291. (Pubitemid 29416814)
13. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. Journal of Neuroscience 1998;18:5151-5159. (Pubitemid 28311932)
14. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. Journal of Immunology 1989;143:718-726. (Pubitemid 19191575)
15. Nicholls DG, Chalmers S. The integration of mitochondrial calcium transport and storage. J Bioenergetics & Biomembranes 2004;36:277-281. (Pubitemid 39619826)
16. Jonas EA. Molecular participants in mitochondrial cell death channel formation during neuronal ischemia. Experimental Neurology 2009;218:203-212.
17. Woodfield KY, Price NT, Halestrap AP. cDNA cloning of rat mitochondrial cyclophilin. Biochimica et Biophysica Acta 1997;1351:27-30. (Pubitemid 27117464)
18. Gunter TE, Gunter KK, Sheu SS, Gavin CE. Mitochondrial calcium transport: Physiological and pathological relevance. American Journal of Physiology 1994;267:313-339.
19. Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. American Journal of Physiology 1990;258: 755-786.
20. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochimica et Biophysica Acta 1995;1241: 139-176.
21. Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 1998;281:2027-2031. (Pubitemid 28475490)
22. 2+ release to cyclosporine A and related compounds. Biochemical Pharmacology 1993;45:641-646. (Pubitemid 23064570)
23. Chopp M, Li Y, Jiang N. Increase in apoptosis and concomitant reduction of ischemic lesion volume and evidence for synaptogenesis after transient focal cerebral ischemia in rat treated with staurosporine. Brain Research 1999;828:197-201. (Pubitemid 29236494)
24. MacManus JP, Linnik MD. Gene expression induced by cerebral ischemia: An apoptotic perspective. Journal of Cerebral Blood Flow & Metabolism 1997;17:815-832. (Pubitemid 27377637)
25. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, et al. Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proceedings of the National Academy of Sciences (USA) 1996;93:6025-6030. (Pubitemid 26190796)
26. Yoshimoto T, Uchino H, He QP, Li PA, Siesjo BK. Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat. Brain Research 2001;899:148-158. (Pubitemid 32324156)
27. Mathur S, Cleary KR, Inamdar N, Kim YH, Steck P, Frazier ML. Overexpression of elongation factor- 1gamma protein in colorectal carcinoma. Cancer 1998;82: 816-821. (Pubitemid 28104158)
28. Cavallius J, Rattan SI, Clark BF. Changes in activity and amount of active elongation factor 1 alpha in aging and immortal human fibroblast cultures. Experimental Gerontology 1986;21:149-157. (Pubitemid 17211323)
29. Shepherd JC, Walldorf U, Hug P, Gehring WJ. Fruit flies with additional expression of the elongation factor EF-1 alpha live longer. Proceedings of the National Academy of Sciences (USA) 1989;86:7520-7521. (Pubitemid 19254487)
30. Wang JF, Engelsberg BN, Johnson SW, Witmer C, Merrick WC, Rozmiarek H, Billings PC. DNA binding activity of the mammalian translation elongation complex: Recognition of chromium- and transplatin-damaged DNA. Archives of Toxicology 1997;71:450-454. (Pubitemid 27250346)
31. Jung M, Kondratyev AD, Dritschilo A. Elongation factor 1 delta is enhanced following exposure to ionizing radiation. Cancer Research 1994;54:2541-2543.
32. DeWille JW, Farmer SJ. Quaking phenotype influences brain lipid-related mRNA levels. Neuroscience Letters 1992;141: 195-198.
33. DeWille JW, Farmer SJ. Postnatal dietary fat influences mRNAS involved in myelination. Developmental Neuroscience 1992;14:61-68.
34. Zumkeller W. The effect of insulin-like growth factors on brain myelination and their potential therapeutic application in myelination disorders. European Journal of Paediatric Neurology 1997;1:91-101. (Pubitemid 127703431)
35. Kubota H, Yokota S, Yanagi H, Yura T. Structures and co-regulated expression of the genes encoding mouse cytosolic chaperonin CCT subunits. European Journal of Biochemistry 1999;262:492-500. (Pubitemid 29266061)
36. Stoldt V, Rademacher F, Kehren V, Ernst JF, Pearce DA, Sherman F. Review: The Cct eukaryotic chaperonin subunits of Saccharomyces cerevisiae and other yeasts. Yeast 1996;12: 523-529.
37. Creutz CE, Liou A, Snyder SL, Brownawell A, Willison K. Identification of the major chromaffin granule-binding protein, chromobindin A, as the cytosolic chaperonin CCT (chaperonin containing TCP-1). Journal of Biological Chemistry 1994;269:32035-32038.
38. Roobol A, Holmes FE, Hayes NV, Baines AJ, Carden MJ. Cytoplasmic chaperonin complexes enter neurites developing in vitro and differ in subunit composition within single cells. Journal of Cell Science 1995;108:1477-1488.
39. Bloom L, Horvitz HR. The Caenorhabditis elegans gene unc- 76 and its human homologs define a new gene family involved in axonal outgrowth and fasciculation. Proceedings of the National Academy of Sciences (USA) 1997;94: 3414-3419. (Pubitemid 27157326)
40. Aitken A. 14-3-3 proteins on the MAP. Trends in Biochemical Sciences 1995;20:95-97.
41. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619-628. (Pubitemid 26386936)
42. Zhang L, Chen J, Fu H. Suppression of apoptosis signalregulating kinase 1-induced cell death by 14-3-3 proteins. Proceedings of the National Academy of Sciences (USA) 1999;96:8511-8515. (Pubitemid 29354822)
43. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proceedings of the National Academy of Sciences (USA) 1997;94:2007-2012. (Pubitemid 27113952)
44. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97:276-281. (Pubitemid 28067314)
45. Cheng Y, Deshmukh M, D'Costa A, Demaro JA, Gidday JM, Shah A, Sun Y, Jacquin MF, Johnson EM, Holtzman DM. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. Journal of Clinical Investigation 1998;101: 1992-1999. (Pubitemid 28226119)
46. Chen J, Nagayama T, Jin K, Stetler RA, Zhu RL, Graham SH, Simon RP. Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. Journal of Neuroscience 1998;18:4914-4928. (Pubitemid 28285400)
47. Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. Journal of Neuroscience 2000;20:4398-4404. (Pubitemid 30396604)
48. Martinou JC, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowski H, Missotten M, Albertini P, Talabot D, Catsicas S, Pietra C, et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994;13: 1017-1030. (Pubitemid 24347313)
49. Wiessner C, Allegrini PR, Rupalla K, Sauer D, Oltersdorf T, McGregor AL, Bischoff S, Bottiger BW, van der Putten H. Neuron-specific transgene expression of Bcl-XL but not Bcl- 2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice. Neuroscience Letters 1999;268: 119-122. (Pubitemid 29305663)
50. Xing H, Zhang S, Weinheimer C, Kovacs A, Muslin AJ. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. The EMBO Journal 2000;19:349-358. (Pubitemid 30072605)
51. Landgraf P, Wahle P, Pape HC, Gundelfinger ED, Kreutz MR. The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity. Journal of Biological Chemistry 2008;283:25036-25045.
52. Landgraf P, Sieg F, Wahle P, Meyer G, Kreutz MR, Pape HC. A maternal blood-borne factor promotes survival of the developing thalamus. The FASEB Journal 2005;19: 225-227. (Pubitemid 40189263)
53. Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi S, Suzuki E, Le Guezennec X, Stunnenberg HG, Krasnov A, et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Molecular Cell 2008;29:92-101.
54. Nagy Z, Tora L. Distinct GCN5/PCAF-containing complexes function as co-Activators and are involved in transcription factor and global histone acetylation. Oncogene 2007;26: 5341-5357. (Pubitemid 47255920)
55. Leng N, Gu G, Simerly RB, Spindel ER. Molecular cloning and characterization of two putative G protein-coupled receptors which are highly expressed in the central nervous system. Brain Research Molecular Brain Research 1999;69: 73-83. (Pubitemid 29238188)
56. Marazziti D, Gallo A, Golini E, Matteoni R, Tocchini- Valentini GP. Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-proteincoupled peptide receptor expressed in brain and testis. Genomics 1998;53:315-324. (Pubitemid 28527634)
57. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001;105:891-902. (Pubitemid 32635090)
58. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392: 605-608. (Pubitemid 28207717)
59. Murakami T, Shoji M, Imai Y, Inoue H, Kawarabayashi T, Matsubara E, Harigaya Y, Sasaki A, Takahashi R, Abe K. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Annals of Neurology 2004;55:439-442. (Pubitemid 38269599)
60. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003;37:911-924. (Pubitemid 36398298)
61. Rezgaoui M, Susens U, Ignatov A, Gelderblom M, Glassmeier G, Franke I, Urny J, Imai Y, Takahashi R, Schaller HC. The neuropeptide head activator is a highaffinity ligand for the orphan G-protein-coupled receptor GPR37. Journal of Cell Science 2006;119:542-549.
62. Bodenmuller H, Schaller HC. Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans. Nature 1981;293:579-580. (Pubitemid 12208461)
63. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease. Journal of Neurochemistry 1999;73:1127-1137. (Pubitemid 29395471)
64. Famulski JK, Vos L, Sun X, Chan G. Stable hZW10 kinetochore residency, mediated by hZwint-1 interaction, is essential for the mitotic checkpoint. Journal of Cell Biology 2008;180:507-520. (Pubitemid 351240700)
65. van Vlijmen T, Vleugel M, Evers M, Mohammed S, Wulf PS, Heck AJ, Hoogenraad CC, van der Sluijs P. A unique residue in rab3c determines the interaction with novel binding protein Zwint-1. FEBS Letters 2008;582:2838-2842.
66. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al. Complement activation by beta-Amyloid in Alzheimer disease. Proceedings of the National Academy of Sciences (USA) 1992;89:10016-10020.
67. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. Journal of Immunology 1994;152:5050-5059.
68. Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Localization and cell association of C1q in Alzheimer's disease brain. Experimental Neurology 1996;138:22-32. (Pubitemid 26107986)
69. Yao J, Harvath L, Gilbert DL, Colton CA. Chemotaxis by a CNS macrophage, the microglia. Journal of Neuroscience Research 1990;27:36-42. (Pubitemid 20321748)
70. O'Barr S, Cooper NR. The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloidbeta primed human monocytes: Implications for Alzheimer's disease. Journal of Neuroimmunology 2000;109:87-94.
71. Benveniste EN, Nguyen VT, O'Keefe GM. Immunological aspects of microglia: Relevance to Alzheimer's disease. Neurochemistry International 2001;39:381-391. (Pubitemid 32907402)
72. Tenner AJ. Complement in Alzheimer's disease: Opportunities for modulating protective and pathogenic events. Neurobiology of Aging 2001;22:849-861. (Pubitemid 34066552)
73. Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. Journal of Neuroscience 2004;24: 6457-6465. (Pubitemid 38971692)
74. Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clinical and Experimental Immunology 2004;137:117-122. (Pubitemid 38869785)
75. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, Taylor SM. Complement mediators in ischemiareperfusion injury. Clinica Chimica Acta 2006;374:33-45.
76. Ten VS, Sosunov SA, Mazer SP, Stark RI, Caspersen C, Sughrue ME, Botto M, Connolly Jr. ES, Pinsky DJ. C1qdeficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice. Stroke 2005;36:2244-2250. (Pubitemid 41429254)
77. Ten VS, Yao J, Ratner V, Sosunov S, Fraser DA, Botto M, Sivasankar B, Morgan BP, Silverstein S, Stark R, et al. Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. Journal of Neuroscience 2010;30:2077-2087.
78. Girod A, Storrie B, Simpson JC, Johannes L, Goud B, Roberts LM, Lord JM, Nilsson T, Pepperkok R. Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum. Nature Cell Biology 1999;1:423-430. (Pubitemid 129502809)
79. White J, Johannes L, Mallard F, Girod A, Grill S, Reinsch S, Keller P, Tzschaschel B, Echard A, Goud B, et al. Rab6 coordinates a novel Golgi to ER retrograde transport pathway in live cells. Journal of Cell Biology 1999;147:743-760.
80. McConlogue L, Castellano F, deWit C, Schenk D, Maltese WA. Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-Amyloid precursor protein. Journal of Biological Chemistry 1996;271:1343-1348. (Pubitemid 26028615)
81. Scheper W, Hoozemans JJ, Hoogenraad CC, Rozemuller AJ, Eikelenboom P, Baas F. Rab6 is increased in Alzheimer's disease brain and correlates with endoplasmic reticulum stress. Neuropathology and Applied Neurobiology 2007;33: 523-532. (Pubitemid 47390081)
82. Mali Y, Zisapels N. Gain of interaction of ALS-linked G93A superoxide dismutase with cytosolic malate dehydrogenase. Neurobiology of Disease 2008;32:133-141.
83. Volkert MR, Elliott NA, Housman DE. Functional genomics reveals a family of eukaryotic oxidation protection genes. Proceedings of the National Academy of Science (USA) 2000;97:14530-14535. (Pubitemid 32016610)
84. Natoli R, Provis J, Valter K, Stone J. Expression and role of the early-response gene Oxr1 in the hyperoxia-challenged mouse retina. Investigative Ophthalmology and Visual Science 2008;49:4561-4567.
85. Inouye S, Seo M, Yamada Y, Nakazawa A. Increase of adenylate kinase isozyme 1 protein during neuronal differentiation in mouse embryonal carcinoma P19 cells and in rat brain primary cultured cells. Journal of Neurochemistry 1998;71:125-133. (Pubitemid 28292542)
86. O'Rourke JF, Pugh CW, Bartlett SM, Ratcliffe PJ. Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Euopean Journal of Biochemistry 1996;241: 403-410. (Pubitemid 26356826)
87. Shahjahan M, Yamada M, Tanaka H, Nakazawa A. Cloning and characterization of the gene encoding bovine mitochondrial adenylate kinase isozyme 3. Gene 1991;107:313-317.
88. Popanda O, Fox G, Thielmann HW. Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochimica Biophysica Acta 1998;1397:102-117. (Pubitemid 28183879)
89. Ogino T, Iwama M, Kinouchi J, Shibagaki Y, Tsukamoto T, Mizumoto K. Involvement of a cellular glycolytic enzyme, phosphoglycerate kinase, in Sendai virus transcription. Journal of Biological Chemistry 1999;274:35999-36008. (Pubitemid 129512911)
90. Shetty S, Muniyappa H, Halady PK, Idell S. Regulation of urokinase receptor expression by phosphoglycerate kinase. American Journal of Respiratory Cell and Molecular Biology 2004;31:100-106. (Pubitemid 38888045)
91. Lay AJ, Jiang XM, Kisker O, Flynn E, Underwood A, Condron R, Hogg PJ. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 2000;408:869-873. (Pubitemid 32016098)
92. Lin L, Jeanclos EM, Treuil M, Braunewell KH, Gundelfinger ED, Anand R. The calcium sensor protein visinin-like protein-1 modulates the surface expression and agonist sensitivity of the alpha 4beta 2 nicotinic acetylcholine receptor. Journal of Biological Chemistry 2002;277: 41872-41878. (Pubitemid 35257499)
93. Schnurra I, Bernstein HG, Riederer P, Braunewell KH. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: A link between calcium sensors and Alzheimer's disease? Neurobiology of Disease 2001;8: 900-909.
94. Steiner JP, Connolly MA, Valentine HL, Hamilton GS, Dawson TM, Hester L, Snyder SH. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Medicine 1997;3:421-428. (Pubitemid 27145684)
95. Gold BG, Gordon HS, Wang MS. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: Lack of evidence for a conditioning lesion-like effect. Neuroscience Letters 1999;267:33-36. (Pubitemid 29251616)
96. Seaton TA, Cooper JM, Schapira AH. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Research 1998;809:12-17. (Pubitemid 29003421)
97. Tatton WG, Chalmers-Redman RM. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? Annals of Neurology 1998;44(3 Suppl 1):134-141.
98. Cassarino DS, Swerdlow RH, Parks JK, Parker Jr WD, Bennett Jr JP. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochemical and Biophysical Research Communications 1998;248:168-173. (Pubitemid 28418206)
99. Wong A, Cortopassi G. mtDNA mutations confer cellular sensitivity to oxidant stress that is partially rescued by calcium depletion and cyclosporin A. Biochemical and Biophysical Research Communications 1997;239:139-145. (Pubitemid 27480330)
100. Sabatini DM, Lai MM, Snyder SH. Neural roles of immunophilins and their ligands. Molecular Neurobiology 1997;15:223-239. (Pubitemid 127719579)
101. Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Lanctot AM, Greco CM, Steinman L, Blau HM. Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study. Muscle Nerve 1997;20:469-478. (Pubitemid 27154638)
102. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993;43:527-532. (Pubitemid 23088486)